Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.0%

38 terminated/withdrawn out of 272 trials

Success Rate

84.5%

-2.1% vs industry average

Late-Stage Pipeline

49%

132 trials in Phase 3/4

Results Transparency

65%

134 of 207 completed trials have results

Key Signals

9 recruiting134 with results28 terminated10 withdrawn

Enrollment Performance

Analytics

Phase 3

92(35.8%)

Phase 2

56(21.8%)

Phase 1

44(17.1%)

Phase 4

40(15.6%)

N/A

24(9.3%)

Early Phase 1

1(0.4%)

257Total

Phase 3(92)

Phase 2(56)

Phase 1(44)

Phase 4(40)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (272)

Showing 20 of 272 trials

NCT07524946Phase 4Recruiting

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

Role: lead

NCT07723924Phase 2Active Not Recruiting

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

Role: lead

NCT07428538Phase 3Recruiting

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

Role: lead

NCT07214272Not ApplicableActive Not Recruiting

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

Role: lead

NCT06673329Phase 1Recruiting

Brodalumab in the Treatment of Immune-Related Adverse Events

Role: collaborator

NCT03988439Phase 4Completed

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Role: lead

NCT07205107Active Not Recruiting

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Role: lead

NCT07285785Phase 4Recruiting

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Role: lead

NCT03596905Phase 2Completed

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

Role: lead

NCT05582434Early Phase 1Active Not Recruiting

Experience With Topical Acne Treatment

Role: collaborator

NCT07187297Not ApplicableRecruiting

A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment

Role: lead

NCT05608499Phase 3Terminated

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Role: collaborator

NCT04892706Phase 2Completed

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Role: lead

NCT05132231Active Not Recruiting

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Role: lead

NCT05976802Phase 4Not Yet Recruiting

Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

Role: lead

NCT02129751Phase 4Not Yet Recruiting

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Role: lead

NCT04356677Phase 1Withdrawn

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2

Role: lead

NCT03240809Phase 4Active Not Recruiting

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Role: lead

NCT04314375Phase 4Recruiting

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Role: lead

NCT00568997Active Not Recruiting

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Role: lead